IDEAYA Biosciences (IDYA) said Monday it has entered into a research collaboration with ATTMOS to develop a physics-based small molecule discovery computational platform for undruggable oncology targets.

The companies will integrate expertise in structural biology, drug discovery, and computational chemistry to develop a high-throughput workflow for absolute binding free energy perturbation predictions of drug candidates.

The collaboration will use the Amber molecular dynamics suite for GPU-accelerated simulations, with IDEAYA incorporating its drug discovery data to train ABFEP-based active learning cycles for efficient small molecule screening, the company said.

Financial details weren't disclosed.

Shares of IDEAYA Biosciences were down more than 2% in recent Monday trading.

Price: 20.00, Change: -0.57, Percent Change: -2.80